Plain-English translation of NCT07185269 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called SSGJ-, an antibody injection designed to help control systemic lupus erythematosus (SLE), a serious autoimmune disease. The medication would be given alongside the medicines you're already taking for lupus. Researchers want to see if the medication reduces disease activity, prevents flares, and is safe for patients.
Many people with lupus continue to experience disease flares and organ damage even while taking standard treatments, and some patients don't tolerate their current medications well. This trial is looking for a new option that could better control lupus and improve outcomes for these patients.
You likely qualify if…
You likely don't qualify if…
If you join, you'll receive injections of either the new medication or a placebo (fake treatment) under your skin, along with your regular lupus medicines. You'll visit the clinic multiple times so doctors can check how you're doing, monitor your disease activity, and watch for any side effects. The study compares different dose levels of the medication to see which works best and is safest.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Enrollment target
~198 participants
Started
September 2025
Primary completion
August 2028
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qinghong Zhou
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.